News BriaCell Therapeutics Corp.

Stocks

BCT

CA1079303071

Biotechnology & Medical Research

Market Closed - Toronto S.E. 15:59:29 2026-09-25 EDT			5-day change	1st Jan Change
6.040 ^CAD	+0.33%		+2.20%	-38.37%

09-14	BriaCell Therapeutics Corp Receives Seventh Consecutive Positive DSMB Recommendation For Pivotal Phase 3 Bria-ABC Study Of Bria-IMT Plus Immune Checkpoint Inhibitor	CI
09-11	Neonc Technologies Holdings, Briacell Therapeutics and Oncolytics Biotech Have Report Clinical and Regulatory Developments Across Brain, Breast and Colorectal Cancer	CI

All News

Mentions Relevance

09-15	Data Safety Monitoring Board Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study	AQ
09-14	Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study	AQ
09-14	BriaCell Therapeutics Corp Receives Seventh Consecutive Positive DSMB Recommendation For Pivotal Phase 3 Bria-ABC Study Of Bria-IMT Plus Immune Checkpoint Inhibitor	CI
09-09	BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center	AQ
09-08	BriaCell Therapeutics Corp. Expands Pivotal Phase 3 Metastatic Breast Cancer Study To Memorial Sloan Kettering Cancer Center	CI
09-08	BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center	AQ
09-01	Certain Common Shares of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026.	CI
09-01	Certain Warrants of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026.	CI
09-01	Certain Options of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026.	CI
09-01	Certain Restricted Share Units of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026.	CI
09-01	Certain Performance Share Units of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026.	CI
08-24	BriaCell Therapeutics Corp. Advances Personalized Melanoma Immunotherapy Vaccine Candidate Bria-MEL+	CI
08-24	BriaCell Therapeutics : Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+(TM)	PU
08-24	BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™	AQ
08-05	BriaCell Gets FDA Approval to Start Phase 1/2a of Prostate Cancer Immunotherapy Study	MT
08-05	Briacell Therapeutics Corp Receives Fda Clearance to Initiate Bria-Pros+ Clinical Study in Prostate Cancer	CI
08-05	BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer	AQ
07-16	BriaCell Opens First Canadian Site For Phase 3 Metastatic Breast Cancer Study	MT
07-16	BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT	AQ
07-16	BriaCell Therapeutics Corp. Opens First Canadian Site For Pivotal Phase 3 Trial In Metastatic Breast Cancer	CI
07-16	BriaCell Therapeutics : Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer	PU
07-16	BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer	AQ
07-15	BriaCell Therapeutics : Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT(TM)	PU
07-15	BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™	AQ
07-07	BriaCell Engages Consulting and Branding Firms to Support Potential Commercialization of Bria-IMT	MT